Myeloma

The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision expected by July 10, 2025.

Throughout my experience with multiple myeloma, I was humbled by the unexpected support and kindness shown to me.

I rediscovered myself through community, writing, music and cooking after my journey with multiple myeloma.

Treatment with fixed-dose subcutaneous Sarclisa plus Pomalyst and dexamethasone was non-inferior to IV Sarclisa in relapsed/refractory multiple myeloma.

After experiencing unexplained symptoms, I was diagnosed with multiple myeloma and underwent a stem cell transplant.

2024 was a year of resilience after a myeloma diagnosis, marked by a return to public speaking, a documentary filming experience and a fundraising walk.

CURE® highlights some top stories from the ASH Annual Meeting, focusing on B-cell acute lymphoblastic leukemia, multiple myeloma and other blood cancers.

As we near the end of 2024, CURE is looking back at the top FDA approval stories of the year.

Patients newly diagnosed with multiple myeloma who are transplant ineligible or deferred may benefit from receiving a Darzalex treatment combination.

This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.

Black patients may be more affected by certain side effects from Talvey compared with White patients with multiple myeloma, an expert told CURE®.

Updated data from the phase 3 DREAMM-7 trial was presented during the 2024 ASH Annual Meeting and Exposition.

Tecvayli alone or plus Revlimid has been found to be safe and may result in high MRD-negativity rates.

The risk for disease progression or death was reduced by 51% with subcutaneous Darzalex Faspro in certain patients with smoldering multiple myeloma.

For patients with transplant-ineligible or -deferred newly diagnosed multiple myeloma, the addition of Darzalex to VRd improved MRD responses as well as progression-free survival.

The FDA has accepted a biologics license application for Blenrep plus bortezomib or pomalidomide for patients with relapsed or refractory multiple myeloma.

Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be presented at an upcoming conference.

Patients with relapsed or refractory multiple myeloma should consider quality of life with survival when choosing the most suitable treatment option.

If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses.

In patients with relapsed or refractory multiple myeloma, KRd56 and KRd27 showed similar effectiveness and safety, but other treatment options may be better.

The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.

From “The Office” star opening up in a new interview to Charley Steiner revealing his multiple myeloma journey, here is this week’s cancer news.

From “Boy Meets World” actress Danielle Fishel discussing her breast cancer surgery to a young TikTok star dying from a rare liver cancer, here’s what’s happening in the cancer space this week.

Ninlaro, Thalomid and dexamethasone followed by Ninlarlo maintenance may improve durability of response in myeloma after stem cell transplantation relapse.

The biologics license application seeks potential approval of a Darzalex Faspro-based regimen for newly diagnosed multiple myeloma ineligible for transplant.